Intrexon Corporation XON and Next Green Wave Holdings Inc. entered into a strategic licensing agreement to utilize Intrexon's Botticelli next-generation plant propagation platform. The companies entered into this agreement to ensure fast production of Next Green Wave's proprietary cannabis cultivars for the California market.
The collaboration between the companies will be two-staged. The first is the optimization phase, in which Intrexon will calibrate Intrexon's Botticelli technology to Next Green Wave's specific cannabis cultivars. The second phase will be the production phase, in which Next Green Wave may utilize the technology in the production of cannabis plantlets for its downstream products and the sale of plantlets to third party producers in California.
Intrexon's Botticelliplatform is an advanced tissue culture technology designed to enable efficient propagation of plants while maintaining genetic purity and product performance. The Botticelli technology offers a more economic solution compared with the conventional clones. The platform will be instrumental in providing high-quality cannabis products for California consumers.
Next Green Wave initially will deploy the Botticelli platform within its Coalinga facility for the California market and will be responsible for maintaining appropriate licensure at the facility.
Share price of Intrexon has declined 42.2% in the past year against the industry’s growth of 18.9%.
We note that, currently, the market for cannabis products pertaining to medical as well as recreational use is in the early stages of expansion. In December 2018, Tilray Inc. TLRY announced that its subsidiary, Tilray Canada Ltd. entered into a global framework agreement with the generic arm of Novartis NVS — Sandoz AG — expanding their current collaboration.
Under the new agreement, Tilray will collaborate with Sandoz to increase the availability of high-quality medical cannabis products across the world. Also, Sandoz will support the commercialization and supply of Tilray’s cannabis non-smokable/non-combustible products for medical use globally.
Both the companies already had collaboration for supply of medical cannabis products in Canada, signed earlier in March 2018.
Intrexon Corporation Price
Intrexon Corporation Price | Intrexon Corporation Quote
Zacks Rank and Stock to Consider
Intrexon currently carries a Zacks Rank #3 (Hold).
A better-ranked stock worth considering is Eli Lilly and Co. LLY, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Lilly’s earnings per share estimates have increased from $5.47 to $5.58 for 2018 and from $5.78 to $5.91 for 2019 over the past 90 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 10.03%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Novartis AG (NVS) : Free Stock Analysis Report
Intrexon Corporation (XON) : Free Stock Analysis Report
Tilray, Inc. (TLRY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research